Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability
Status:
Active, not recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The present study will be a multicenter, prospective phase II-study comparing efficacy of
allogeneic SCT for patients with myelofibrosis who have a suitable stem cell donor after a 3
months Ruxolitinib induction therapy with patients who lack a suitable stem cell donor and
will continue to receive Ruxolitinib.
Phase:
Phase 2
Details
Lead Sponsor:
Universitätsklinikum Hamburg-Eppendorf
Collaborators:
Clinical Trial Center North (CTC North GmbH & Co. KG) CTC North (CRO) Novartis